TABLE 1.
Baseline Demographics
| Demographic | All participants (n = 111) | Advanced chronic coronary artery disease (n = 59) | Acute myocardial infarction (n = 52) | P |
|---|---|---|---|---|
| Age (y) | 65.7 ± 7.49 | 66.7 ± 7.6 | 64.5 ± 7.3 | NS |
| Sex (male) | 98 (88%) | 55 (93%) | 43 (83%) | NS |
| Past medical history | ||||
| Prior acute coronary syndrome | 49 (44%) | 42 (71%) | 45 (17%) | <0.001 |
| Previous PCI | 52 (47%) | 46 (78%) | 6 (12%) | <0.001 |
| Previous CABG | 15 (14%) | 15 (26%) | 0 (0%) | <0.001 |
| Prior cerebrovascular disease | 7 (6%) | 2 (3%) | 5 (10%) | |
| Duke score | <0.001 | |||
| 2 | 19 (18%) | 1 (2%) | 18 (35%) | |
| 3 | 30 (28%) | 8 (15%) | 22 (43%) | |
| 4 | 26 (24%) | 19 (35%) | 7 (14%) | |
| 5 | 26 (24%) | 23 (42%) | 3 (6%) | |
| 6 | 6 (6%) | 4 (7%) | 2 (4%) | |
| Cardiovascular risk factors | ||||
| Smoking habit | <0.008 | |||
| Nonsmoker | 43 (44%) | 19 (32%) | 24 (46%) | |
| Current smoker | 28 (29%) | 11 (19%) | 17 (33%) | |
| Former smoker | 26 (27%) | 29 (49%) | 11 (21%) | |
| Diabetes mellitus | ||||
| None | 92 (83%) | 49 (83%) | 43 (83%) | NS |
| Type 1 | 2 (2%) | 0 (0%) | 2 (4%) | NS |
| Type 2 | 17 (15%) | 10 (17%) | 7 (14%) | NS |
| Hypertension | 51 (46%) | 32 (54%) | 19 (37%) | NS |
| Total cholesterol (mmol/L) | 4.44 ± 1.31 | 4.29 ± 0.96 | 4.61 ± 1.59 | |
| Systolic blood pressure (mm Hg) | 137 ± 27 | 146 ± 19 | 128 ± 31 | <0.001 |
| Medications | ||||
| Aspirin | 111 (100%) | 52 (100%) | 59 (100%) | NS |
| Statin | 108 (97%) | 50 (96%) | 58 (98%) | NS |
| ACE-I/ARB | 90 (81%) | 45 (87%) | 45 (76%) | NS |
| β-blocker | 83 (75%) | 37 (71%) | 46 (78%) | NS |
| Baseline biochemistry | ||||
| Troponin I (ng/L) | 8,595 ± 16,838 | 10 ± 34 | 17,676 ± 20,633 | <0.001 |
| Creatinine (μmol/L) | 82.16 ± 16.03 | 80.7 ± 12.8 | 83.7 ± 18.9 | NS |
| Risk scores | ||||
| REACH score | 11.00 (9.00–14.00) | 14.00 (11.50–15.50) | 9.00 (8.00–10.00) | <0.001 |
| SMART score | 18.00 (14.00–28.00) | 22.00 (15.50–32.50) | 15.00 (12.00–22.00) | 0.004 |
| Radiation doses | ||||
| Total dose–length product (mGy⋅cm) | 821.00 (621.00–964.00) | 843.00 (637.50–1134.00) | 792.50 (597.00–863.75) | 0.019 |
| Initial 18F-fluoride dose (MBq) | 244.40 (240.25–248.17) | 246.02 (241.79–248.85) | 243.15 (238.57–246.72) | 0.015 |
| Serial 18F-fluoride dose (MBq) | 240.72 (236.29–246.75) | 241.00 (236.03–247.35) | 240.70 (237.12–245.27) | NS |
NS = not statistically significant; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.
Qualitative data are number and percentage; continuous data are median and interquartile range or mean ± SD.